CDC 998
Latest Information Update: 04 Dec 2019
Price :
$50 *
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories
- Mechanism of Action Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 19 Nov 2003 No development reported - Phase-I for Inflammation in USA (unspecified route)
- 31 Dec 2000 Phase-I clinical trials for Inflammation in USA (Unknown route)